TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
NEO

NeoGenomics Inc

Healthcare · Diagnostics & Research

19.30$ -1.2% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

NeoGenomics Inc (NEO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 202 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement NEO
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
61 60 62 62 63 68 63 68 69 76 96 102 105 107 106 87 125 126 116 122 121 126 117 125 129 139 137 147 152 156 156 165 168 172 168 181 188 190 187 202 766
33 33 34 35 34 35 36 37 37 39 48 53 54 57 60 59 71 69 74 69 74 80 79 81 80 82 82 87 90 88 91 92 93 95 95 104 107 114 106 110 437
27 27 27 31 29 33 27 31 32 37 45 49 51 50 46 28 54 57 42 53 47 45 38 44 49 57 55 60 62 68 65 72 75 77 73 77 80 76 81 92 329
1.0 0.9 0.9 0.9 1.3 0.6 1.0 1.1 0.4 0.5 1.2 2.6 2.6 2.1 2.1 2.1 2.0 2.1 2.5 3.5 7.4 8.5 13 13 7.3 6.7 7.4 7.5 5.3 7.1 7.6 7.9 7.7 8.0 10 9.0 8.7 9.2 9.5 11 38
19 20 21 23 18 22 17 21 21 26 32 30 33 33 36 35 36 37 40 55 64 62 60 56 64 55 62 60 61 60 66 63 67 64 65 72 70 64 66 64 263
26 27 27 30 31 29 25 30 28 34 45 44 47 48 52 47 49 52 57 75 87 87 90 84 88 83 90 90 87 86 96 94 96 96 101 125 107 87 99 102 395
1.4 -2.9 -0.1 1.3 -2.3 4.5 2.5 0.8 3.9 2.8 2.5 4.5 3.7 2.3 -5.3 -19 4.7 5.5 -15 -22 -40 -42 -52 -40 -40 -26 -35 -30 -24 -19 -31 -22 -21 -18 -28 -48 -27 -11 -18 -9.8 -66
1.5 5.5 1.4 1.4 1.4 1.4 1.5 1.4 1.9 1.5 1.8 1.3 0.2 0.4 0.8 1.5 2.5 2.2 1.2 0.9 1.3 1.7 1.3 0.9 0.1 0.9 1.8 1.8 1.7 1.7 1.7 1.7 1.6 1.6 1.6 0.9 0.6 0.6 0.6 0.8 2.6
-0.1 -8.4 -1.5 -0.1 -4.8 2.9 1.1 -0.7 2.1 1.4 -4.4 2.2 3.5 2.4 -5.9 -18 2.2 7.6 -21 73 -23 -44 -53 -41 -40 -26 -34 -27 -21 -15 -28 -19 -18 -16 -26 -46 -26 -12 -18 1.8 -55
0.0 -2.2 -0.8 -0.1 0.3 -2.1 0.4 -0.4 0.1 1.1 -2.0 0.2 1.3 -3.9 1.1 -11 -0.3 -7.9 1.0 -2.4 -2.8 -2.4 -3.8 -5.7 -2.8 -2.8 -2.9 -2.3 -2.9 -1.0 -0.6 -0.4 -0.2 -0.8 0.3 -0.7 0.7 -2.5 -0.5 -0.4 -2.7
-0.1 -6.2 -1.2 0.5 -4.3 5.0 0.6 -0.4 2.0 0.4 -2.4 2.0 2.1 6.3 -7.0 -6.8 2.6 15 -22 76 -20 -42 -49 -35 -37 -23 -31 -24 -19 -14 -27 -19 -18 -15 -26 -45 -27 -9.9 -17 2.2 -52
7.4 3.3 5.1 7.0 3.5 9.9 7.6 5.9 9.4 8.8 5.2 11 11 10 3.6 -8.0 14 19 -9.0 85 -2.8 -26 -29 -20 -22 -8.3 -14 -6.6 -1.6 4.8 -7.7 0.8 1.8 3.7 -6.3 -28 -10.0 4.6 -0.6 19 13

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?